Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.

2021年12月27日，西班牙马德里罗氏跨国制药行业的总部。

Cristina Arias | Cover | Getty Images

克里斯蒂娜·阿里亚斯 | 封面 | 盖蒂图片社

Swiss pharmaceutical giant

瑞士制药巨头

Roche

罗氏

said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech

周三表示，已达成一项价值高达53亿美元的协议，以开发丹麦生物技术

Zealand Pharma

捷灵亚制药

's obesity drug candidate, as the two firms seek to compete in the burgeoning weight loss drug market.

的肥胖症药物候选品，因这两家公司希望在蓬勃发展的减肥药市场中竞争。

The deal will see the two companies co-develop and co-commercialize petrelintide, Zealand Pharma's

该协议将使两家公司共同开发和商业化 Zealand Pharma 的 petrelintide，

amylin analog

艾米林类似物

as a standalone therapy, as well as a fixed-dose combination with Roche's lead incretin asset CT-388.

作为一种独立疗法，以及与罗氏领先的肠促胰岛素药物CT-388的固定剂量组合。

Under the agreement, Zealand Pharma will receive upfront cash payments of $1.65 billion, with the potential of milestone payments taking the total to up to $5.3 billion, depending on phase-3 trials and sales development, Roche said in a statement.

根据协议， Zealand Pharma 将获得 16.5 亿美元的预付款，如果三期试验和销售发展顺利，还有可能获得里程碑付款，总金额最高可达 53 亿美元，罗氏在一份声明中表示。

Shares of Zealand Pharma jumped 29% shortly after the announcement, and were trading up 23% by 10:5- a.m. London time, while Roche added 4.6%.

Zealand Pharma的股价在消息公布后不久飙升了29%，并在伦敦时间上午10点5分时上涨了23%，而罗氏则上涨了4.6%。

Shares of obesity drug giant

肥胖症药物巨头的股票

Novo Nordisk

诺和诺德

, meanwhile, slipped 3.9% during Wednesday's session as

与此同时，周三的交易时段下跌了3.9%，因为

Eli Lilly

礼来公司

dipped 1.5% in pre-market trade.

盘前交易下跌了1.5%。

Zealand Pharma CEO and President Adam Steensberg told CNBC that the deal showed the two companies' 'strong commitment to lead in the obesity space in the future.'

Zealand Pharma首席执行官兼总裁亚当·斯滕斯伯格告诉CNBC，这笔交易显示了两家公司“未来在肥胖领域领先的强烈承诺”。

'Roche has convinced us that they have ambition to take leadership in this therapeutic space,' he told CNBC via video call Wednesday.

“罗氏已经让我们相信，他们有雄心在这个治疗领域取得领导地位，”他周三通过视频电话向CNBC表示。

The Danish biotech has long pointed to amylin analogs as the

这家丹麦生物技术公司长期以来一直将胰淀素类似物作为

'next generation'

'下一代'

of weight loss treatment. They work by mimicking a hormone that is co-secreted with insulin in the pancreas to increase satiety. This differs from GLP-1 agonists, which mimic incretin hormones produced in the gut to suppress appetite and regulate blood sugar.

它们通过模拟一种与胰岛素在胰腺中共同分泌的激素来增加饱腹感。这不同于GLP-1受体激动剂，后者模拟肠道中产生的肠促胰岛素激素来抑制食欲和调节血糖。

'In contrast to GLP-1s that make make people lose appetite, petrelintide can help people feel fuller faster,' Steensberg said.

“与让人失去食欲的GLP-1不同，petrelintide可以帮助人们更快感到饱腹，”斯滕斯伯格说。

watch now

立即观看

VIDEO

视频

3:09

3:09

03:09

03:09

Zealand Pharma seeks partner for its 'next generation' weight loss drug

Zealand Pharma为其“下一代”减肥药寻求合作伙伴

Street Signs Europe

欧洲路标